Optimal timing of non-ablative local radiation and subsequent surgery in a mesothelioma mouse model resulted in an increase of activated, antigen-specific CD8+ T cells in the tumor and a protective, long-term immunological response via memory CD4+ T cells. Radiation synergized with concomitant CTLA-4 blockade, eliciting a call for clinical evaluation of the combined therapies.

PURPOSE: How best to sequence and integrate immunotherapy into standard of care is currently unknown. Clinical protocols with accelerated non-ablative hypofractionated radiation followed by surgery could provide an opportunity to implement immune checkpoint blockade.

Experimental Design: We therefore assessed the impact of non-ablative hypofractionated radiation on the immune system in combination with surgery in a mouse mesothelioma model. Blunt surgery (R1 resection) was used to analyze the short term impact and radical surgery (R0 resection) was used to analyze the long-term impact of this radiation protocol before surgery.

Results: Non-ablative hypofractionated radiation led to a specific immune activation against the tumor associated with significant upregulation of CD8+ T cells limiting the negative impact of an incomplete resection. The same radiation protocol performed 7 days before radical surgery led to a long term antitumor immune protection that was primarily driven by CD4+ T cells. Radical surgery alone or radical surgery with a short course of non-ablative radiation completed 24 hours before radical surgery did not provide this vaccination effect. Combining this radiation protocol with CTLA-4 blockade provided better results than radiation alone. The effect of PD-1 or PD-L1 blockade with this radiation protocol was less effective than the combination with CTLA-4 blockade.

Conclusions: A specific activation of the immune system against the tumor contributes to the benefit of accelerated, hypofractionated radiation before surgery. Non-ablative hypofractionated radiation combined with surgery provides an opportunity to introduce immune checkpoint blockades in the clinical setting.

Author Info: (1) Division of Thoracic Surgery, Toronto General Hospital. (2) Division of Thoracic Surgery, University of Toronto. (3) Division of Thoracic Surgery, University Health Network. (4

Author Info: (1) Division of Thoracic Surgery, Toronto General Hospital. (2) Division of Thoracic Surgery, University of Toronto. (3) Division of Thoracic Surgery, University Health Network. (4) Thoracic surgery, TGRI. (5) University of Toronto. (6) University of Toronto. (7) University of Toronto. (8) Radiation Oncology, Princess Margaret Hospital. (9) Division of Thoracic Surgery, Toronto General Hospital marc.deperrot@uhn.ca.